Fig. 6

Recombinant TAT-CRYAB protein inhibits inflammatory response of intestinal epithelial cells. a HT29 and Caco-2 cells were incubated with TAT-CRYAB (500 ng/ml) for indicated times. CRYAB expression was assessed by immunoblotting. b TNF-α, IL-6, IL-1β, and IL-8 were inhibited by TAT-CRYAB treatment. HT29 and Caco-2 cells were treated with TNF-α (10 μg/ml) for 6 h in the absence or presence of pretreatment of recombinant TAT-CRYAB (5 μg/ml) for 12 h. The cytokine mRNAs were measured by qRT-PCR; *p < 0.05, **p < 0.01, ***p < 0.001. c The phosphorylation of p65 and IκBα was inhibited by TAT-CRYAB. The levels of p-p65, p65, p-IκBα, and IκBα in different treated cells were analyzed by immunoblotting with specific antibodies. All data are shown from three three independent experiments